Friday, 03 Apr 2020

You are here

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX). 

This was a study to compare the risk of serious infections in chronic plaque psoriasis patients treated with either infliximab or non-biologic systemic therapies, including MTX.  (This was not a comparison of various biologic agents in psoriasis).

Investigators grouped several non-biologic systemic therapies, including methotrexate, ciclosporin, acitretin, fumaric acid esters, psoralen-ultraviolet A or hydroxycarbamide and analyzed rates of serious infections (SIE) associated with death, hospitalisation or the need for intravenous antimicrobial therapy.

Among 3843 psoriasis patients accrued up to October 2016, the SIE rates were significantly higher in the infliximab cohort (47.8 per 1000 person-years) compared to the on non-biologic systemic cohort (14.2 per 1000 person-years) and the adjusted hazard ratio was 1.95, (95% CI 1.01, 3.75 vs. DMARDSs) and was also higher when compared to methotrexate only (adjHR 2.96, 95% CI 1.58, 5.57).

As has been shown in other studies, the risk of serious infection was highest in the first 6 months of therapy (adjHR 3.49, 95% CI 1.14, 10.70).

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Start with Anti-TNF in RA? Not So Fast

The suggestion to hit rheumatoid arthritis (RA) early and hard with biologic therapies itself took a hit in a new study.

Use of first-line etanercept (Enbrel) plus methotrexate in very early RA was not associated with a substantially higher rate of remission compared with a strategy of treat-to-target methotrexate monotherapy, a randomized open-label trial found.

Best of 2019 - The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Psoriasis Risk Increased with TNF Inhibitors in Juveniles

Children with inflammatory diseases who were treated with tumor necrosis factor (TNF) inhibitors had a higher rate of incident psoriasis than those not exposed to these biologics, a single-center retrospective study found.

The Shame Behind Adalimumab Biosimilars

JAMA has an article this week on the shift from biologic drugs to less expensive therapeutic biosimilar agents. The impact of biosimilars can be easily represented by the shift from adalimuamb - a biologic with nearly $19 billion in sales in 2018 - to any one of the four FDA approved biosimilars for adalimumab (see the daily download for slides on new adalimumab and other biosimilars).

Pain Persists Despite TNF Inhibitor Use

Control of pain in patients with rheumatoid arthritis (RA) often focuses on control of inflammation as a means to better control pain. However, a new claims data study shows that while anti-tumor necrosis factor inhibitor (TNFi) may lower the use of opioids, the reduction is nominal, suggesting that a substantial amount of pain is not adequately addressed by TNFi - a potent anti-inflammatory approach.